AstraZeneca, Generic Drugmakers Face Nexium Class Action
This article is for subscribers only.
AstraZeneca Plc and three generic-drug makers must face class-action allegations they overcharged consumers by delaying low-cost versions of the heartburn medication Nexium for six years, a judge ruled.
U.S. District Judge William Young in Boston ruled yesterday that union health plans and insurance companies can join together in pursuing antitrust claims against AstraZeneca, Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Inc. and Ranbaxy Laboratories Ltd.